NCT01061411 - Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 6, 2010

Primary Completion Date

October 14, 2015

Study Completion Date

April 21, 2017

Conditions

Clear Cell Sarcoma of the KidneyRecurrent Renal Cell CarcinomaStage III Renal Cell CancerStage IV Renal Cell Cancer

Interventions

DRUG

Dalteparin

Given SC

OTHER

Pharmacological Study

Correlative studies

DRUG

Sunitinib Malate

Given PO

Trial Locations (4)

Roswell Park Cancer Institute, Buffalo

City of Hope Comprehensive Cancer Center, Duarte

Academ Zienkenhuis Bij De University, Amsterdam

VU University Medical Center, Amsterdam